 |
Find a CAS® Registry Number(s) for a Drug?
TOPIC: Finding the correct nomenclature for a particular drug is an important part of searching for pharmaceutical information. Drug directory databases let you identify generic names, trade names, lab codes, CAS® Registry Numbers, synonyms for drugs and/or other molecular entities.
In this example, you want to find the CAS Registry Number for Gilenya, a drug to treat multiple sclerosis, so that you can use it to find more information in the biomedical literature. A CAS Registry Number is a unique number for each chemical substance and can be very effectively used to search for information about specific chemicals in several Dialog databases.
You can search for a substance name in Embase® (File 73, 72), which is the most current biomedical bibliographic database available today and provides an easy way to retrieve the CAS Registry Number for a drug. File 73 covers 1974 to the present and File 72 covers 1994 to the present.
COMMAND SUMMARY
BEGIN 72
EXPAND GILENYA
EXPAND E3
EXPAND R2
SELECT R10
TYPE S1/9/1
HOW TO...
|
1. BEGIN Embase (File 72) to search for a chemical substance. (Alternatively you may use B 73 to search the whole file from 1974 forward.)
|
? b72
File 72:EMBASE 1993-2012/Sep 18
(c) 2012 Elsevier B.V.
Set Items Description
--- ----- ----------- |
|
2. EXPAND (E) using the drug name.
|
? e gilenya
Ref File Items Total RT Index-term
E1 72 8 1 GILENIA
E2 72 1 GILENSTAM
E3 72 149 1 *GILENYA
E4 72 2 GILERI
E5 72 1 GILERT
E6 72 609 GILES
E7 72 1 GILES AND KENDALL
E8 72 3 GILESI
E9 72 5 GILESII
E10 72 1 GILESIUS
E11 72 1 GILEST
E12 72 4 GILET |
|
3. EXPAND the appropriate E number (E3).
Note: use the EXPAND command with parentheses around the drug name to bypass the first level. E.g, EXPAND (GILENYA).
A drug entry may be cross-referenced to the preferred term, which is recognized when a U is in the Type field.
|
? e e3
Ref File Items Total Type RT Index-term
R1 72 149 1 *GILENYA
R2 72 2595 U 9 FINGOLIMOD |
|
4. EXPAND the appropriate R number.
|
? e r2
Ref File Items Total Type RT Index-term
R1 72 2595 9 *FINGOLIMOD
R2 72 103 B 149 ALKANOLAMINE
R3 72 45317 B 180 IMMUNOSUPPRESSIVE AGENT
R4 72 0 S 1 FINGOLIMOD HYDROCHLORIDE
R5 72 1456 S 1 FTY 720
R6 72 1150 S 1 FTY720
R7 72 8 S 1 GILENIA
R8 72 149 S 1 GILENYA
R9 72 0 S 1 2 AMINO 2 [2 (4 OCTYLPHENYL)ETHYL]
1,3 PROPANE
R10 72 2283 S 1 RN=162359-56-0
Enter P or PAGE for more |
|
5. SELECT the appropriate R number(s).
|
? s r10
S1 2283 RN='162359-56-0' |
|
6. TYPE a record using Format 9 to see a complete record.
Note: Partial record shown.
Use Format 8 to see just the CAS Registry Number and the descriptor terms.
|
? t s1/9/1
Dialog eLink:
1/9/1
DIALOG(R)File 72: EMBASE
(c) 2012 Elsevier B.V. All rights reserved.
0088142293 EMBASE/MEDLINE No: 2012515810
The safety risks of innovation: The FDA's expedited drug development pathway
Moore T.J.; Furberg C.D.
Institute for Safe Medication Practices, 101 N Columbus St, Alexandria, VA 22314, United States
Author email: tmoore@ismp.org
Corresp. Author/Affil: Moore T.J.: Institute for Safe Medication Practices, 101 N Columbus St, Alexandria, VA 22314, United States
Corresp. Author Email: tmoore@ismp.org
JAMA - Journal of the American Medical Association ( J. Am. Med. Assoc. ) (United States) August 29, 2012 , 308/9 (869-870)
CODEN: JAMAA ISSN: 0098-7484 eISSN: 1538-3598
Item Identifier (DOI): 10.1001/jama.2012.9658
URL: http://jama.jamanetwork.com/data/Journals/JAMA/24832/jvp120059_869_ 870.pdf
Document Type: Journal ; Short Survey Record Type: Citation
Language: English
Number of References: 10
Drug Descriptors:
beta1a interferon--clinical trial--ct; beta1a interferon--drug comparison --cm; dabigatran--adverse drug reaction--ae; dabigatran--clinical trial--ct ; dabigatran--drug comparison--cm; dabigatran--drug therapy--dt; dabigatran --oral drug administration--po; fingolimod--adverse drug reaction--ae; fingolimod--clinical trial--ct; fingolimod--drug comparison--cm; fingolimod --drug dose--do; fingolimod--drug therapy--dt; fingolimod--pharmacology--pd ; placebo; vandetanib--adverse drug reaction--ae; vandetanib--clinical trial--ct; warfarin--drug comparison--cm; warfarin--drug therapy--dt
Medical Descriptors:
* drug approval; *drug program; *drug safety; *food and drug administration
atrioventricular block--side effect--si; bleeding--side effect--si; cancer risk; cancer therapy; drug activity; drug legislation; drug megadose; drug withdrawal; heart atrium fibrillation--drug therapy--dt; heart rate; heart ventricle arrhythmia; human; liver toxicity--side effect--si; low drug dose ; lung function; multiple sclerosis--drug therapy--dt; multiple sclerosis --prevention--pc; opportunistic infection--side effect--si; overall survival; pharmacist; prescription; priority journal; progression ...
Medical Terms (Uncontrolled): Expedited Drug Development Pathway; medullary thyroid cancer
CAS Registry Number: 162359-56-0 (fingolimod); 338992-00-0, 338992-48-6, 443913-73-3 ( vandetanib); 129-06-6, 2610-86-8, 3324-63-8, 5543-58-8, 81-81-2 (warfarin)
SECTION HEADINGS:
Neurology and Neurosurgery
Cancer
Public Health, Social Medicine and Epidemiology
Clinical and Experimental Pharmacology
Drug Literature Index
Adverse Reactions Titles |
RELATED HOW DO I...? SOLUTIONS
NEED HELP?
Contact the Dialog Knowledge Center
Within North America 1 800 3 DIALOG (334 2564)
Outside North America 00 800 33 DIALOG (33 34 2564)
Web Form www.dialog.com/contacts/webform
|
|
